Gevorg Grigoryan - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Role: Chief Technology Officer
Signature: /s/ Michael Wolf, Attorney-in-Fact
Issuer symbol: GENB
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2026, 17:51:38 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Grigoryan Gevorg	Chief Technology Officer	GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE	/s/ Michael Wolf, Attorney-in-Fact	02 Mar 2026	0002108976

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GENB	Stock Option (Right to Buy)	Award	$0	+295,608		$0.000000	295,608	26 Feb 2026	Common Stock	295,608	$16.00	Direct	F1
transaction	GENB	Stock Option (Right to Buy)	Award	$0	+196,368		$0.000000	196,368	26 Feb 2026	Common Stock	196,368	$16.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.
F2	The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.